Ownership history in MARSHALL WACE, LLP · 7 quarters on record
This page tracks every 13F SEC filing in which MARSHALL WACE, LLP reported a position in TOURMALINE BIO I (TRML). Data includes quarterly share count, position size as % of portfolio, estimated market value, and end-of-quarter stock price — sourced directly from SEC EDGAR 13F filings.
| Quarter | Action | Shares | Change | Chg % | % of Fund | Mkt Value | Price (EOQ) |
|---|---|---|---|---|---|---|---|
| 2025 Q3 | ADDED | 143,731 | +44,565 | +44.9% | 0.01% | $6.9M | — |
| 2025 Q1 | REDUCED | 99,166 | -16,925 | -14.6% | 0.00% | $1.5M | — |
| 2024 Q4 | REDUCED | 116,091 | -22,103 | -16.0% | 0.00% | $2.4M | — |
| 2024 Q3 | REDUCED | 138,194 | -32,253 | -18.9% | 0.00% | $3.6M | — |
| 2024 Q2 | ADDED | 170,447 | +31,029 | +22.3% | 0.00% | $2.2M | — |
| 2024 Q1 | ADDED | 139,418 | +94,422 | +209.8% | 0.00% | $3.2M | — |
| 2023 Q4 | INITIATED | 44,996 | — | — | 0.00% | $1.2M | — |
As of 2025 Q3 — sorted by position size